MBX Biosciences doses first participant in Phase 1 trial of obesity drug MBX 4291

MBX Biosciences, Inc.

Phase 1 trial is randomized, double-blind, placebo-controlled; Part A: 5 SAD cohorts (8 each, 3:1 randomization).
Part B: 3 MAD cohorts (4 weekly doses, 8 each, 3:1 randomization); plus optional 12-week MAD cohorts (30 each, 2:1).
Topline results anticipated in 2027; preclinical data support once-monthly dosing and improved GI tolerability.
MBX 4291 is a long-acting GLP-1/GIP co-agonist prodrug for obesity, designed for best-in-class weight loss.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.